Last reviewed · How we verify

NCT06619899: PAP-SP

Post-activation Potentiation and Sprinting Performance

Completed NA Last updated 4 December 2024
What this trial tests

NA trial testing PAP exercise with 0% body mass in Sprint Performance in 15 participants. Completed in 15 November 2024.

Timeline
1 September 2024
Primary endpoint
15 November 2024
15 November 2024

Quick facts

Lead sponsorUniversity of Thessaly
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposescreening
Enrollment15
Start date1 September 2024
Primary completion15 November 2024
Estimated completion15 November 2024
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

University of Thessaly

Who can join

Adults 18 to 30, any sex, with Sprint Performance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Scientific data regarding the post-activation potentiation (PAP) phenomenon on sprinting performance is scarce, especially regarding the effect of performing pre-conditioning power exercises on subsequent sprinting performance. Additionally, there is no data regarding the rate of fatigue onset when power pre-conditioning exercise before sprints are performed repeatedly at the same training session. This research will provide important information to coaches and athletes for the design of an optimum training program for the maximization of the athletes' performance and the avoidance of injuries.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Thessaly trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06619899.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing